Unal Hanzade Aybuke, Basarı Ahmet, Celiker Opal Sezgi, Cakar Turhan Keziban Sanem, Asik Ibrahim, Ozgencil Gungor Enver
Department of Anesthesiology and Reanimation, Division of Pain Medicine, Ankara University School of Medicine, Ankara 06230, Turkey.
Department of Anesthesiology and Reanimation, Ankara University School of Medicine, Ankara 06230, Turkey.
J Clin Med. 2024 May 21;13(11):3027. doi: 10.3390/jcm13113027.
: Compare the effects of greater occipital nerve (GON) and sphenopalatine ganglion (SPG) blocks on headache intensity and duration, number of headache days, and disability in patients with episodic migraine. : In this prospective single-blind randomized study, patients with episodic migraine were randomly divided into two groups: GON and SPG block groups. Patients received blocks once a week for 4 weeks, and once a month for 2 months. The number of headache days, the headache duration, numeric rating scale (NRS) scores, and number of acute medical treatments were assessed before the procedures and 1 month, 2 months, and 3 months after the procedures. Disability was evaluated using the migraine disability assessment (MIDAS) questionnaire at baseline and 3 months after treatment. This study protocol is registered at ClinicalTrials.gov (NCT06243874.). 19 patients in the GON block group and 18 patients in the SPG block group were evaluated. Significant improvements in pain severity, headache duration, number of headache days, and the need for acute medical treatment were observed in the 1st, 2nd, and 3rd months compared to baseline in the two groups ( < 0.001). There were significant improvements in the MIDAS scores in the third month ( < 0.001). The GON block group showed a greater reduction in headache intensity, duration, number of headache days, and MIDAS scores compared to the SPG block group in the 3rd month ( < 0.001). : GON block reduces headache duration, intensity, the number of headache days, and the need for acute medical treatment much more than SPG block in patients with episodic migraine.
比较枕大神经（GON）阻滞和蝶腭神经节（SPG）阻滞对发作性偏头痛患者头痛强度、持续时间、头痛天数及残疾程度的影响。：在这项前瞻性单盲随机研究中，发作性偏头痛患者被随机分为两组：GON阻滞组和SPG阻滞组。患者每周接受一次阻滞，共4周，之后每月接受一次阻滞，共2个月。在治疗前以及治疗后1个月、2个月和3个月评估头痛天数、头痛持续时间、数字评分量表（NRS）得分以及急性药物治疗次数。在基线期和治疗后3个月使用偏头痛残疾评估（MIDAS）问卷评估残疾程度。本研究方案已在ClinicalTrials.gov（NCT06243874）注册。对GON阻滞组的19例患者和SPG阻滞组的18例患者进行了评估。与基线相比，两组在第1、2和3个月时疼痛严重程度、头痛持续时间、头痛天数以及急性药物治疗需求均有显著改善（<0.001）。第三个月时MIDAS评分有显著改善（<0.001）。在第3个月时，与SPG阻滞组相比，GON阻滞组在头痛强度、持续时间、头痛天数和MIDAS评分方面的降低幅度更大（<0.001）。：在发作性偏头痛患者中，GON阻滞比SPG阻滞更能显著降低头痛持续时间、强度、头痛天数以及急性药物治疗需求。
Zotero 插件